BioSpace News Archive

BerGenBio ASA announced the first patient was dosed in a Phase 1b/2a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line Non-Small Cell Lung Cancer patients harboring STK11 mutations.

Regenative Labs (Regenative), a leading HCT/P manufacturer, is pleased to announce the publication of its new paper, “The Durability and Efficacy of Cryopreserved Human Umbilical Cord Tissue Allograft for the Supplementation of Cartilage Defects Associated with the Sacroiliac Joint: A Case Series,” with Dr. Albert Lai.

Prestige Biopharma Limited, a Singapore-based biopharmaceutical company, has developed a first-in-class diagnostic kit for pancreatic cancer.

AbCheck s.r.o. announced that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”.

QurAlis Corporation announced it has closed an oversubscribed $88 million Series B financing, bringing the total funds raised to $143.5 million.

Evelo Biosciences, Inc. (Nasdaq: EVLO), today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights.

Ring Therapeutics today announced that it raised $86.5 million in Series C funding, bringing its total funds raised to date to $230 million.

KalVista Pharmaceuticals, Inc . today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2023.

Biotechnology startup Tiamat Sciences announced its $2 million seed-extension financing round led by 8090 Industries with participation from new and existing investors.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, announced new results from exploratory analyses including delayed time to key clinical progression events in people living with amyotrophic lateral sclerosis who were treated with CNM-Au8® in the HEALEY ALS Platform Trial over the 6-months of the double-blind period.